
Articles
-
1 week ago |
proactiveinvestors.com.au | Emily Jarvie
SanDisk (NASDAQ:SNDK) shares moved higher after Bank of America initiated coverage on the developer and manufacturer of data storage devices based on NAND flash technology with a ‘Buy’ rating and price objective of $61, representing upside of about 38% at the time of writing.
-
1 week ago |
proactiveinvestors.com | Emily Jarvie |Angela Harmantas
MiningUranium This record is published on behalf of Standard Uranium Ltd, a paid client of ProactiveAbout this content Disclaimer No investment advice About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022.
-
1 week ago |
proactiveinvestors.com | Emily Jarvie
FinanceBlockchain & Crypto This record is published on behalf of Fineqia International Inc, a paid client of ProactiveAbout this content Disclaimer No investment advice About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022.
-
1 week ago |
proactiveinvestors.com | Emily Jarvie |Angela Harmantas
Peru is ramping up efforts to cement its role as a global mining powerhouse, forecasting $4.8 billion in new investment in 2025 as demand for copper and other critical minerals accelerates. The Energy and Mines Ministry expects output to rise in 2025, as global producers and junior miners double down on one of the world's richest copper reserves. Copper output is expected to rise to 2.8 million metric tons this year.
-
1 week ago |
proactiveinvestors.com | Emily Jarvie
Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate of drug development using artificial intelligence (AI). The expanded collaboration builds on prior work in which GATC provided AI-based analysis supporting Lisata’s certepetide drug candidate.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →